A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

None had been diagnosed with Alzheimer disease and related dementias at the start of the study. The researchers discovered that people who took GLP-1 receptor agonists (like Ozempic) or a type of ...

In the second study, a team led by Allie Seminer ... effects and that they are not guaranteed to prevent dementia." Newsweek has contacted Ozempic manufacturer Novo Nordisk for comment.

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been ... and that they are not guaranteed to prevent dementia. 'The study had important limitations including a ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

The scientists found that two medications significantly reduce the risk of developing dementia in life. A new study, ...

What else does weight-loss drug Ozempic do? 5 unexpected health benefits - Emerging scientific research indicates that ...

1:54 GLP-1 drugs like Ozempic, Wegovy reduce Alzheimer’s risk for those with diabetes Two major studies published Monday in JAMA Neurology found that GLP-1 medications are linked to a lower risk ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...